FDA Proposes New Pathway for Approving Customized Rare Disease Treatments

The proposed guidelines aim to spur development of bespoke therapies that have only been tested in a handful of patients.

Feb. 23, 2026 at 11:18pm

Got story updates? Submit your updates here. ›

The U.S. Food and Drug Administration has laid out a proposal to create a new pathway for approving customized treatments for patients with rare, hard-to-treat diseases, including genetic conditions. The preliminary guidelines would allow experimental therapies to be commercialized even if they have only been tested in a small number of patients, a shift long sought by patient advocates and researchers focused on rare diseases.

Why it matters

This proposal addresses a key challenge in the pharmaceutical industry, where rare diseases are often considered unprofitable due to the difficulties of conducting large clinical trials. The new pathway could encourage more investment and innovation in treatments for these underserved patient populations.

The details

The FDA's proposed "plausible mechanism" pathway would authorize experimental treatments if researchers can confirm the therapy successfully targeted the patient's genetic or biological abnormality, even without large-scale clinical trials. This is a shift from the FDA's traditional drug approval process, which requires drugmakers to demonstrate safety and effectiveness in studies comparing patients receiving the therapy to those receiving a placebo or alternative intervention.

  • The FDA announced the proposal on February 23, 2026.
  • The agency will take public comments on the draft guidance for 60 days before finalizing the new pathway.

The players

Marty Makary

FDA Commissioner who said the new pathway is a priority to "remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases."

Children's Hospital of Philadelphia and the University of Pennsylvania

A team of researchers at these institutions designed a therapy using the CRISPR gene editing tool to treat a baby born with a rare disease that causes ammonia buildup in the blood.

Got photos? Submit your photos here. ›

What they’re saying

“It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases.”

— Marty Makary, FDA Commissioner (ksgf.com)

What’s next

The FDA will finalize the new "plausible mechanism" pathway after reviewing public comments for 60 days.

The takeaway

This proposed FDA policy shift could significantly boost development and access to customized treatments for rare diseases, which have long been overlooked by the pharmaceutical industry due to the challenges of conducting large clinical trials. If implemented, it represents an important regulatory change to support innovation and better serve underserved patient populations.